Last $0.22 USD
Change Today 0.00 / 0.00%
Volume 140.1K
HEB On Other Exchanges
As of 8:04 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

hemispherx biopharma inc (HEB) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/14 - $0.49
52 Week Low
01/23/15 - $0.21
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hemispherx biopharma inc (HEB) Related Bloomberg News

View More Bloomberg News

hemispherx biopharma inc (HEB) Related Businessweek News

No Related Businessweek News Found

hemispherx biopharma inc (HEB) Details

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company products comprise Ampligen, an experimental drug, which is under clinical development for the treatment of chronic fatigue syndrome, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma. Its products also include Alferon N Injection, an injectable formulation of natural alpha interferon for the treatment of certain categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of influenza, seasonal influenza, and other emerging viruses. The company has a strategic alliance with Bioclones (Pty) Ltd. to develop various projects. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

39 Employees
Last Reported Date: 03/14/14
Founded in 1990

hemispherx biopharma inc (HEB) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.0M
Executive Vice Chairman, Chief Financial Offi...
Total Annual Compensation: $553.8K
Chief Medical Officer and Medical Director
Total Annual Compensation: $265.5K
Compensation as of Fiscal Year 2013.

hemispherx biopharma inc (HEB) Key Developments

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors

Hemispherx Biopharma, Inc. announced further progress on developing Ampligen® (rintatolimod) as a potential therapeutic complement to a new molecular class of anti-tumor drugs termed immune checkpoint inhibitors or PD-1 inhibitors (also called Programmed Death inhibitors). PD-1 inhibitors act to unleash the body's own immune system to scavenge/destroy tumors: remarkable success to date clinically has been reported by Bristol Meyers Squibb (BMS), Merck, Genetech and Novartis on a variety of human tumors including malignant melanoma and metastatic renal cancer with PD inhibitors. In some of these cases, full regulatory approval of commercialization for PD-1 inhibitors has already been received internationally or is expected to be received shortly. Objective tumor regressions are typically seen in approximately 10 to 25% of patients with PD-1 checkpoint inhibitors, such compounds have been generally well-tolerated clinically with a few exceptions noted to date. Hemispherx has active ongoing antitumor programs with Ampligen® in this research area at Georgia Regents University Cancer Center (GRU) and the Cancer Center at the University of Pittsburgh (UP). The laboratory program at GRU is supported in part by sponsored research of Hemispherx whereas the UP cancer program is supported internally at the University and by various National Institutes of Health Grants. Key to further progression in this field is to improve efficacy and speed to market by determining which combination strategies yield high priority and which techniques can be used to overcome technical challenges of clinical monitoring and predicting immune response. Investigation of immune competent models that can be effectively translated into the clinic with expert knowledge has thus become invaluable. To that end, Professor Esteban Celis (at GRU) first reported that in animal models a dsRNA analogue of Ampligen®, Poly I: Poly C, significantly increased survival in animal tumors when administered in combination with PD-1 inhibitors. In follow on animal experiments with Ampligen®, Celis has demonstrated anti-tumor properties of Ampligen® similar to those of classical PD-1 inhibitors with a resultant long term survival advantage in mouse melanoma. In particular, his experiments suggest analogous actions of Ampligen® against malignant melanoma in the animal model. Mice protected by Ampligen® and/or a PD-1 inhibitor were resistant to rechallenge with viable melanoma cells in the absence of drug(s), indicating a "memory effect", which is most likely mediated by anti-melanoma cytotoxic CD8+ cells. Immune mechanisms may account for an apparent long term benefit of Ampligen® in melanoma.

Hemispherx Biopharma Announces Earnings Results for the Third Quarter Nine Months Ended September 30, 2014

Hemispherx Biopharma announced earnings results for the third quarter nine months ended September 30, 2014. For the quarter, the company reported net loss (including non-cash effects) of approximately $4,202,000 or $0.02 per share against $5,136,000 or $0.03 per share a year ago. Total revenues were $45,000, compared to $36,000 for the same quarter ended September 30, 2013. For the nine months, the company reported net loss (including non-cash effects) of approximately $12,994,000 or $0.07 per share against $13,030,000 or $0.08 per share a year ago. Total revenues were $157,000, compared to $114,000 for the same period ended September 30, 2013.

Hemispherx Biopharma and Sage Group Prevails in Multi-Million Dollar Federal Lawsuit

Hemispherx Biopharma, Inc. announced that a federal judge in Delaware has dismissed all claims against Hemispherx and the Sage Group brought by Cato Capital in an order and decision dated September 29, 2014. The decision comes following a three day trial before a judge in the United States District Court for the District of Delaware, which considered several multimillion dollar claims brought by Cato Capital. The Court's order completely vindicated Hemispherx and the Sage Group of any wrongdoing and denied Cato Capital's claims against Hemispherx for breach of contract and fraudulent inducement. On October 14, 2014, Hemispherx' lead trial counsel James J. Black, filed a motion for recovery of fees and costs seeking recovery for Hemispherx of approximately one million dollars based upon contractual fee shifting provisions in the subject contract.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEB:US $0.22 USD 0.00

HEB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $273.25 USD 0.00
AstraZeneca PLC 4,727 GBp -34.50
Baxter International Inc $71.38 USD 0.00
Medigene AG €3.73 EUR -0.009
Sarepta Therapeutics Inc $12.30 USD +0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation HEB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 217.4x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 137.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMISPHERX BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at